| pubmed-article:6860533 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:6860533 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:6860533 | lifeskim:mentions | umls-concept:C0683140 | lld:lifeskim |
| pubmed-article:6860533 | lifeskim:mentions | umls-concept:C0038742 | lld:lifeskim |
| pubmed-article:6860533 | lifeskim:mentions | umls-concept:C0441472 | lld:lifeskim |
| pubmed-article:6860533 | lifeskim:mentions | umls-concept:C1704675 | lld:lifeskim |
| pubmed-article:6860533 | lifeskim:mentions | umls-concept:C1554184 | lld:lifeskim |
| pubmed-article:6860533 | lifeskim:mentions | umls-concept:C0332120 | lld:lifeskim |
| pubmed-article:6860533 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:6860533 | pubmed:dateCreated | 1983-8-11 | lld:pubmed |
| pubmed-article:6860533 | pubmed:abstractText | The effects of sulphinpyrazone administration on the metabolic and renal clearances of theophylline in man were investigated. Sulphinpyrazone increased total plasma theophylline clearance by 22%. This was the sum of increases in metabolic clearances by 3-demethylation (32%), 1-demethylation (30%) and 8-oxidation (22%) and of a decrease in renal clearance (27%). It is proposed that sulphinpyrazone has differential effects on at least two forms of cytochrome P-450 inhibiting one enzyme or group of enzymes which metabolises tolbutamide, phenytoin and S(-)warfarin and inducing a form (or forms) which metabolises theophylline, antipyrine and R(+)warfarin. | lld:pubmed |
| pubmed-article:6860533 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6860533 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6860533 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6860533 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6860533 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6860533 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6860533 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6860533 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6860533 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6860533 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6860533 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6860533 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6860533 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6860533 | pubmed:language | eng | lld:pubmed |
| pubmed-article:6860533 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6860533 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:6860533 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6860533 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6860533 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:6860533 | pubmed:month | May | lld:pubmed |
| pubmed-article:6860533 | pubmed:issn | 0306-5251 | lld:pubmed |
| pubmed-article:6860533 | pubmed:author | pubmed-author:BirkettD JDJ | lld:pubmed |
| pubmed-article:6860533 | pubmed:author | pubmed-author:MinersJ OJO | lld:pubmed |
| pubmed-article:6860533 | pubmed:author | pubmed-author:AttwoodJJ | lld:pubmed |
| pubmed-article:6860533 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:6860533 | pubmed:volume | 15 | lld:pubmed |
| pubmed-article:6860533 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:6860533 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:6860533 | pubmed:pagination | 567-9 | lld:pubmed |
| pubmed-article:6860533 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:6860533 | pubmed:meshHeading | pubmed-meshheading:6860533-... | lld:pubmed |
| pubmed-article:6860533 | pubmed:meshHeading | pubmed-meshheading:6860533-... | lld:pubmed |
| pubmed-article:6860533 | pubmed:meshHeading | pubmed-meshheading:6860533-... | lld:pubmed |
| pubmed-article:6860533 | pubmed:meshHeading | pubmed-meshheading:6860533-... | lld:pubmed |
| pubmed-article:6860533 | pubmed:meshHeading | pubmed-meshheading:6860533-... | lld:pubmed |
| pubmed-article:6860533 | pubmed:meshHeading | pubmed-meshheading:6860533-... | lld:pubmed |
| pubmed-article:6860533 | pubmed:meshHeading | pubmed-meshheading:6860533-... | lld:pubmed |
| pubmed-article:6860533 | pubmed:year | 1983 | lld:pubmed |
| pubmed-article:6860533 | pubmed:articleTitle | Evidence for a dual action of sulphinpyrazone on drug metabolism in man: theophylline-sulphinpyrazone interaction. | lld:pubmed |
| pubmed-article:6860533 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:6860533 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6860533 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6860533 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6860533 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6860533 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6860533 | lld:pubmed |
